98%
921
2 minutes
20
Baker's yeast is one of the most important and widely used cell factories for recombinant protein production. Many strategies have been applied to engineer this yeast for improving its protein production capacity, but productivity is still relatively low, and with increasing market demand, it is important to identify new gene targets, especially targets that have synergistic effects with previously identified targets. Despite improved protein production, previous studies rarely focused on processes associated with intracellular protein retention. Here we identified genetic modifications involved in the secretory and trafficking pathways, the histone deacetylase complex, and carbohydrate metabolic processes as targets for improving protein secretion in yeast. Especially modifications on the endosome-to-Golgi trafficking was found to effectively reduce protein retention besides increasing protein secretion. Through combinatorial genetic manipulations of several of the newly identified gene targets, we enhanced the protein production capacity of yeast by more than fivefold, and the best engineered strains could produce 2.5 g/L of a fungal α-amylase with less than 10% of the recombinant protein retained within the cells, using fed-batch cultivation.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6255153 | PMC |
http://dx.doi.org/10.1073/pnas.1809921115 | DOI Listing |
Haematologica
September 2025
Department of Molecular Hematopathology, Okayama University Graduate School of Health Sciences, Okayama.
Idiopathic multicentric Castleman disease (iMCD) is a rare lymphoproliferative disorder characterized by systemic inflammation and lymphadenopathy. Two major clinical subtypes, idiopathic plasmacytic lymphadenopathy (iMCD-IPL) and iMCD with thrombocytopenia, anasarca, fever, renal dysfunction/reticulin fibrosis, and organomegaly (iMCD-TAFRO), exhibit distinct pathophysiologic mechanisms. While interleukin-6 (IL-6) is known to be elevated in iMCD, the differences in IL-6 production sources between subtypes remain unclear.
View Article and Find Full Text PDFJ Mater Chem B
September 2025
Malopolska Centre of Biotechnology, Jagiellonian University, Krakow 30-387, Poland.
Degradation during production and delivery is a significant bottleneck in developing biomolecular therapies. Protein cages, formed by engineered variants of lumazine synthase, present an effective strategy for the microbial production and isolation of labile biomolecular therapies. Genetic fusion of the target polypeptide to a cage component protomer ensures its efficient encapsulation within the cage during production in host bacterial cells, thereby protecting it from degradation.
View Article and Find Full Text PDFChembiochem
September 2025
Department of Chemistry and Biochemistry, University of Wisconsin-Eau Claire, 101 Roosevelt Avenue., Eau Claire, Wisconsin, 54701, USA.
The development of synthetically-useful biocatalysts requires characterizing the behavior of an enzyme under conditions amenable to preparative-scale reactions. Whole cells harboring the catalyst of interest are often used in such reactions, as protein purification is laborious and expensive. However, monitoring reaction rates when using whole cells is challenging, as cellular debris precludes the use of a continuous assay.
View Article and Find Full Text PDFJ Cosmet Dermatol
September 2025
Laboratoires VIVACY, France.
Background: Superficial injection of hyaluronic acid (HA)-based gels is a widely used method to restore skin quality and achieve a more youthful appearance. While the clinical benefits of such procedures are well established, their biological mechanisms of action remain poorly understood.
Objective: This study aimed to evaluate the effectiveness of two cross-linked HA gels (IPN-12.
J Am Chem Soc
September 2025
Kekulé Institute for Organic Chemistry and Biochemistry, University of Bonn,Gerhard-Domagk-Straße 1,Bonn 53121,Germany.
Terpene synthases produce a remarkable structural diversity from acyclic precursors through complex carbocation cascades. Here, we report the crystal structure of the bacterial sesterterpene synthase StvirS bound to geranylfarnesyl thiopyrophosphate (GFSPP), revealing a preorganized active site that enforces a defined folding of the C25 backbone. Guided by this structure, active-site engineering at 11 positions yielded 23 enzyme variants and 13 new sesterterpenes.
View Article and Find Full Text PDF